Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
500 participants
INTERVENTIONAL
1999-04-30
2007-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Brief Therapies for Problem Gambling Substance Abusers
NCT00685048
A Pilot SMART Design for Pathological Gamblers
NCT00685724
Adding Contingency Management to Treatment as Usual for Disordered Gambling.
NCT02613754
Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management
NCT00350649
Contingency Management to Reinforce Attendance to Cognitive Behavioral Treatment for Gambling Disorder
NCT07016100
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This open-label study will last a total of 9 months. Participants will be randomly assigned to one of four groups. Group 1 will have no intervention and will be instructed to call if they experience any gambling problems. Group 2 will receive 5 minutes of education on the hazards of heavy gambling. In addition, they will receive a 1-page brochure on problem gambling and its consequences. Group 3 will receive a 1-hour session of MET focused on increasing commitment to change by raising awareness of personal consequences of gambling. Group 4 will receive the same MET session as Group 3, as well as three 1-hour sessions of CBT focused on identifying specific social and mood cues associated with gambling. Treatment will end at Week 4. Participants will have two follow-up sessions held over the phone at Week 6 and again 9 months after enrollment. Gambling behavior, employment status, alcohol and drug use, psychiatric problems, and family problems will be assessed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
5 Minutes of Simple Advice
2
Motivational Enhancement Therapy (MET)
3
Cognitive Behavioral Therapy (CBT)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
5 Minutes of Simple Advice
Motivational Enhancement Therapy (MET)
Cognitive Behavioral Therapy (CBT)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Two or more gambling episodes per month for 2 months prior to enrollment
* Has spent at least $50 per month on gambling for 2 months prior to enrollment
Exclusion Criteria
* Severe cognitive impairment
* Currently receiving treatment for gambling
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Donaghue Medical Research Foundation
OTHER
UConn Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nancy M Petry, PhD
Role: PRINCIPAL_INVESTIGATOR
UConn Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
LMG
Bridgeport, Connecticut, United States
University of Connecticut Health Center
Farmington, Connecticut, United States
CSAC
Hartford, Connecticut, United States
Southern CT State University
New Haven, Connecticut, United States
LMG
Stamford, Connecticut, United States
University of Connecticut
Storrs, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DF#00-121
Identifier Type: -
Identifier Source: secondary_id
99-205
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.